Introduction
Angiotension-converting enzyme inhibitors (ACEIs) have been shown to be beneficial in the treatment of diabetic and nondiabetic chronic kidney disease, heart failure and coronary heart disease. [1] [2] [3] The Seventh Report of the Joint National Committee suggests ACEIs be used to treat hypertension among patients with these conditions. 4 Despite these recommendations and clinical data supporting the benefits of ACEIs, patients are often not treated with adequate doses or they are simply not prescribed at all. 5 Given the benefits of ACEI therapy in the aforementioned populations, the lack of ACEI administration is surprising. The reticence of physicians to prescribe ACEIs may in part be related to safety concerns regarding renal failure. Clinical inertia, lack of system support and competing mandates may account for lack of appropriate ACEI prescription as well. 6 Physicians often check serum creatinine levels following the initiation of an ACEI to ensure that should such an adverse event occur, it will be recognized and the medication stopped. In spite of this concern, there remains a significant paucity of information available regarding the risk of such an event. Few precise recommendations exist regarding whether and when to check serum creatinine levels following ACEI administration. In addition, little has been published about how high a rise in serum creatinine warrants cessation of treatment, or the risk of such an event among patients with normal baseline serum creatinine. This provides little reassurance to clinicians who fear a marked rise in serum creatinine following ACEI initiation.
In an effort to more accurately delineate the risks of renal failure among Kaiser Permanente Northwest members, we conducted a retrospective review of patients who were prescribed lisinopril, a longacting ACEI. We reviewed whether patients with normal serum creatinine levels (p1.2 mg/dl) had subsequent serum creatinine levels checked, how significantly they changed and whether the patient suffered a subsequent adverse event.
Methods
A computerized search using the Kaiser Permanente Northwest's electronic medical record was conducted to identify continuously enrolled patients 40 or more years of age taking lisinopril between July 1, 2000 and June 30, 2002. Electronic data regarding patient age and gender were collected. Additionally, the Kaiser Permanente Diabetes Mellitus (DM) registry was used to identify patients with the diagnosis of DM and the Coronary Artery Disease (CAD) registry was used to identify patients with the diagnoses of coronary artery disease or peripheral vascular disease. Patients are included in the DM registry if they had pharmacy or laboratory diagnoses in their medical record consistent with the DM. This registry has previously been validated with a sensitivity and specificity of 99%. 7 Patients included in the CAD registry had either undergone specific procedures (ie coronary artery bypass surgery) or had a diagnosis consistent with the presence of CAD in their medical record.
Laboratory data were electronically searched to obtain the most recent serum creatinine and potassium drawn for each patient between July 1, 1999 and June 30, 2002 prior to ACEI initiation. Additionally, serum creatinine and potassium levels checked during the 6-month period following ACEI administration were identified and recorded.
Patient demographics were compared regarding age, listing in the DM or CAD registries and baseline creatinine level. Subsequent increased serum creatinine and potassium levels were quantified. Patients with baseline creatinine levels p1.2 mg/dl and postlisinopril increases in creatinine 42.5 mg/ dl were identified and underwent chart review to discern whether an adverse event (hospitalization, dialysis, etc) had occurred in conjunction with rise in creatinine. Patients without follow-up creatinine levels were assumed to have had no adverse response to lisinopril initiation.
Results
The total Kaiser Permanente Northwest patient population on June 30, 2002 was 453 772. A total of 18 977 patients were prescribed lisinopril be- . Among this population, 9586 (50.5%) were male and 9391 (49.5%) female. The number of patients in the DM and/or CAD registries (n ¼ 10 209) were greater than those who were not (n ¼ 8768). A total of 15 140 (79.8%) patients had serum creatinine drawn prior to lisinopril initiation, and 3837 (20.2%) did not. Among those with prelisinopril creatinine, 13 567 patients had creatinine p1.2 mg/ dl, while 1573 had previous creatinine greater than 1.2 mg/dl. A total of 918 patients had baseline creatinine p1.2 mg/dl and subsequent creatinine 41.2 mg/dl. Following lisinopril initiation, 13 166 patients had serum creatinine checked within the ensuing 6 months, and 5811 patients did not. Of the 15 140 patients who had prelisinopril creatinine drawn, 10 567 (69.8%) also had serum creatinine checked within the ensuing 6 months ( Table 1 and Figure 1 ). Figure 1 Profile of patients included in analysis.
Significant increases in serum creatinine following ACEIs administration
In all, 31 patients had baseline creatinine of p1.2 mg/dl and a subsequent rise to 42.5 mg/dl in the 6 months following lisinopril initiation. The mean peak creatinine rise was 3.7 mg/dl and the mean period of time from lisinopril initiation to creatinine check was over 7 weeks. Most patients in this group were not listed in the DM or CAD registries. Chart reviews revealed that most patients in this population had a subsequent decrease in serum creatinine to less than 2.5 mg/dl 6 months following the creatinine rise. No patients developed end-stage renal disease, none were lost to follow-up and three patients died in the ensuing 6 months ( Table 2) . Two patients died secondary to infection and one died after a congestive heart failure exacerbation. Most patients with a significant rise in serum creatinine were neither diabetic nor had coronary artery disease. Diagnoses commonly associated with rises in serum creatinine included congestive heart failure exacerbation, dehydration and infection.
The prevalence of patients with normal creatinine (p1.2 mg/dl) and subsequent rise in creatinine (41.2 mg/dl) was 6.8%. This percentage does not include patients without postlisinopril creatinine levels. The inclusion of patients who did not have prelisinopril creatinine did not change the prevalence with postlisinopril creatinine 41.2 mg/dl (6.8%). The prevalence of patients with normal serum creatinine and subsequent rise in creatinine 42.5 mg/dl was 0.2% (Table 3) .
Discussion
Many clinicians may not be prescribing ACEIs due to concerns about a rise in serum creatinine. Our study suggests that patients with preceding creatinines p1.2 mg/dl have an approximately 7% chance of developing an increased serum creatinine following lisinopril initiation. This is a somewhat greater percentage of patients than identified in other Significant increases in serum creatinine following ACEIs administrationstudies. One of the largest studies involved was the Gruppo Italiano per lo Studio Sopravvivenza nell'Infarto Miocardico-3 Study (GISSI-3), which reported that only 0.6% of patients with initially normal creatinine (p132 mmol/l) had a significant rise in serum creatinine (X265 mmol/l). 8 This discrepancy may be due to the use of only 5 or 10 mg of lisinopril in the GISSI-2 study. A meta-analysis by Bakris found that 1-9% of patients with diabetic nephropathy had a fall in GFR 1 month following ACEI initiation. 9 Discrepancies in these studies likely reflect different populations studied.
Our study suggests ESRD is an unlikely outcome among patients who have a significant rise in serum creatinine. Moreover, only 0.2% of patients with serum creatinine p1.2 mg/dl had a subsequent serum creatinine 42.5 mg/dl. Interestingly, this number changes little when patients who did not have preceding creatinine checked were added. This is similar to results from GISSI-2, in which patients with low serum creatinine had a 0.6% risk of significant creatinine elevation 6 weeks after lisinopril initiation.
These results suggest that the risk of a significant long-standing creatinine elevation is unlikely following initiation of lisinopril. Furthermore, the risk of such a rise is more likely to be associated with exacerbations of congestive heart failure, dehydration, or infection. As a result, measuring serum creatinine levels following lisinopril initiation among patients with normal creatinine levels may be modestly beneficial. It is among patients with acute illnesses (congestive heart failure exacerbation, infection, dehydration, etc) where monitoring creatinine levels may be even more important.
